Trials / Withdrawn
WithdrawnNCT02203474
A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Dose-Ranging Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), Placebo HFA BAI, and Open-Label SPIRIVA® HandiHaler® (18 mcg) in Patients With Chronic Obstructive Pulmonary Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to demonstrate the superiority of tiotropium hydrofluoroalkane (HFA) breath actuated inhaler (BAI) to placebo HFA BAI following repeated, once-daily dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiotropium HFA BAI 5 mcg | |
| DRUG | Tiotropium 18 mcg Capsule | |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2014-07-30
- Last updated
- 2021-11-09
Source: ClinicalTrials.gov record NCT02203474. Inclusion in this directory is not an endorsement.